Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 5Phase 2 5Phase 1/2 3Phase 1 3Phase EARLY_PHASE1 2

Status

Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 82Neoplasms 78Colorectal Neoplasms 67Neoplasm Metastasis 65Prostatic Neoplasms 61Leukemia, Myeloid, Acute 61Ovarian Neoplasms 57Recurrence 55Pancreatic Neoplasms 55Multiple Myeloma 52Melanoma 40Triple Negative Breast Neoplasms 36Lung Neoplasms 36Glioblastoma 36Squamous Cell Carcinoma of Head and Neck 34Endometrial Neoplasms 33Lymphoma, Non-Hodgkin 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Lymphoma, Large B-Cell, Diffuse 28Carcinoma, Renal Cell 28Lymphoma 27Stomach Neoplasms 26Small Cell Lung Carcinoma 26Carcinoma, Hepatocellular 26Myelodysplastic Syndromes 25Lymphoma, B-Cell 25Advanced Solid Tumor 25Leukemia, Lymphocytic, Chronic, B-Cell 24Brain Neoplasms 24

Interventions

belantamab mafodotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoglobulin Light-chain Amyloidosis × 90 days × Clear all
NCT05145816 2026-05-07

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07081646 2026-03-24

ALACRITY

Alexion Pharmaceuticals, Inc.

Phase 1/2 Recruiting
91 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06569147 2026-03-06

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Brigham and Women's Hospital

Phase 1/2 Recruiting
49 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡